251 286 - Biotech Bayern
251 286 - Biotech Bayern
251 286 - Biotech Bayern
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
siRion GmbH<br />
BIOTECH DEVICES & REAGENTS<br />
SIRION’s expertise comprises services for RNAi expression and solutions for<br />
customized gene expression. In virtually any cell type, SiRIONs newly developed<br />
QSTEP technology allows for optimal knock down efficiency, which means<br />
also cells resistant to transfection. By means of the proprietary viral QSTEP technology,<br />
the limitations of conventional siRNA transfection are eliminated.<br />
When using QSTEP frozen cells, no time consuming and tedious optimization of<br />
transfection protocols, which give little reproducible results, are needed. QSTEP<br />
guaranties high reproducibility, reliability and optimal knock down efficiencies<br />
for our customer’s assays.<br />
Sloning BioTechnology GmbH<br />
BIOTECH DEVICES & REAGENTS<br />
Keywords: Automation, Genomics, PCR, Proteomics<br />
Sloning BioTechnology GmbH is a <strong>Biotech</strong> company in the vicinity of Munich,<br />
Germany, which has developed a novel way of synthesising double-stranded<br />
DNA molecules (gene constructs). Based on a library of standardised, doublestranded<br />
building blocks, gene constructs are synthesised on a fully automated<br />
robotic platform. Purely research driven in the past, the company has succesfully<br />
entered the market in 2006 as a service provider of customised genes and high<br />
quality SlonoMax mutant libraries.<br />
Sloning's mission is to industrialise the synthesis of artificial genes to unlock<br />
the huge potential of genome data for drug development and production<br />
applications.<br />
SpheroTec GmbH<br />
BIOTECH PRECLINICAL SERVICES<br />
Keywords: Drug Development, Oncology, Tissue Engineering / Cell Culture<br />
SpheroTec means Spherotechnology. Spheroids are miniature tumors in vitro<br />
mimicking microtumors in cancer patients. The three-dimensional tissue like<br />
model allows predictive drug testing with respect to efficacy, cell toxicity,<br />
drug penetration into the microtumor and pharmakodynamic in a very early<br />
preclinical phase of drug development. The advantages are obvious: early<br />
identification of ineffective and highly toxic drugs, effective selection of therapeutically<br />
relevant drugs, high probability of success in advanced clinical trials<br />
and thus FDA approval as well as reduction of animal experiments, time and<br />
costs. The Spherotechnology is appropriate for all kind of drugs including antibodies<br />
and small molecules.<br />
Contact:<br />
Dr. Lars Behrend<br />
Am Klopferspitz 19<br />
D-82152 Martinsried<br />
Phone: +49 (0) 89 7009619-99<br />
Fax: +49 (0) 89 7009619-98<br />
E-Mail: info@sirion-biotech.de<br />
Internet: www.sirion-biotech.de<br />
Contact:<br />
Sascha Meyer<br />
Zeppelinstr. 4<br />
D-82178 Puchheim<br />
Phone: +49 (0) 89 809095-0<br />
Fax: +49 (0) 89 809095-50<br />
E-Mail: info@sloning.de<br />
Internet: www.sloning.com<br />
Contact:<br />
Dr. Barbara Mayer<br />
Am Klopferspitz 19<br />
D-82152 Martinsried<br />
Phone: +49 (0) 89 7095-6438<br />
Fax: +49 (0) 89 7095-6263<br />
E-Mail: bmayer@spherotec.com<br />
Internet: www.spherotec.com<br />
105
Change language